| Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript |
Zai Lab Limited (NASDAQ:ZLAB ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Jonathan Wang - Chief Business Officer Conference Call Participants Michael Yee - Jefferies Louise Chen - Scotiabank Yen-Der Li - Leerink Partners Li Watsek - Cantor Yigal Nochomovitz - Citi Anupam Rama - JPMorgan Jack Lin - Morgan Stanley Rebecca Liang - Bernstein Linhai Zhao - Goldman Sachs Operator Hello, ladies and gentlemen, thank you for standing by, and welcome to Zai Lab's First Quarter 2025 Financial Results Conference Call. At this time, all participants are in listen-only mode. |
seekingalpha.com |
2025-05-11 12:55:31 |
Czytaj oryginał (ang.) |
| Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-08 15:01:54 |
Czytaj oryginał (ang.) |
| Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2025, along with recent product highlights and corporate updates. “In the first quarter, we continued to advance both our global pipeline and commercial business,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are rapidly expanding our global portfolio, having recently presented promising data for two next-generation oncology t. |
businesswire.com |
2025-05-08 10:00:00 |
Czytaj oryginał (ang.) |
| Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational oncology therapies that it has global rights to, ZL-6201, a novel leucine-rich repeat-containing protein 15 (LRRC15) antibody-drug conjugate (ADC) targeting multiple solid tumors, and ZL-1222, an innovative anti-PD-1/ interleukin-12 (IL-12) immunocytokine for cancer immunotherapy, during poster se. |
businesswire.com |
2025-04-25 17:12:00 |
Czytaj oryginał (ang.) |
| Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The application is intended for patients whose disease is locally advanced or metastatic, or where surgical resection is likely to. |
businesswire.com |
2025-04-21 11:30:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy |
Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-04-15 17:05:35 |
Czytaj oryginał (ang.) |
| Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? |
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. |
zacks.com |
2025-04-14 14:10:36 |
Czytaj oryginał (ang.) |
| Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company's internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research. |
businesswire.com |
2025-03-26 09:00:00 |
Czytaj oryginał (ang.) |
| Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth |
Zai Lab Limited is an innovative Pharma partnering with US and European Pharmas to secure approvals for, and market their drugs in China. ZLAB stock has surged over 105% in the past year, driven by strong revenue growth and ambitious plans for future drug launches. The company aims to achieve $2bn in annual revenues by 2028, with key drugs like Vyvgart and Cobenfy leading the charge. |
seekingalpha.com |
2025-03-21 19:16:29 |
Czytaj oryginał (ang.) |
| Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks |
ZLAB's Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB's main growth drivers. ZLAB's ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), and Optune (pancreatic/lung cancer) that could become major revenue verticals in China. |
seekingalpha.com |
2025-03-20 15:05:11 |
Czytaj oryginał (ang.) |
| Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. “In China, cervical cancer is a serious health concern with approximately 150,000 new cases diagnosed annually1,”. |
businesswire.com |
2025-03-12 21:30:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet |
The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-03-04 12:55:33 |
Czytaj oryginał (ang.) |
| Zai Lab Announces Participation in Investor Conferences in March 2025 |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in March 2025: Leerink Partners 2025 Global Healthcare Conference Fireside Chat: Monday, March 10, 2025, 9:20 a.m. EST Location: Miami, FL Jefferies Biotech on the Beach Summit Time: Tuesday, March 11, 2025 Location: Miami, FL A live webcast of the fireside chat will be available on th. |
businesswire.com |
2025-03-03 09:30:00 |
Czytaj oryginał (ang.) |
| Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript |
Zai Lab Limited (NASDAQ:ZLAB ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Head of Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Michael Yee - Jefferies Yen-Der Li - Leerink Partners Reena Patel - Citi Linhai Zhao - Goldman Sachs Li Wang Watsek - Cantor Fitzgerald Po Han Lin - Morgan Stanley Operator Hello, ladies and gentlemen. Thank you for standing by and welcome to Zai Lab's Fourth Quarter and Full Year 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-02-28 00:46:16 |
Czytaj oryginał (ang.) |
| Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights and corporate updates. “2024 was a defining year for Zai Lab, marked by strong sales growth, financial strength, and significant pipeline progress. As we look ahead, 2025 is set to be a transformative year with VYVGART's continued momentum, three new product launches, progress with ZL-1310, and. |
businesswire.com |
2025-02-27 08:00:00 |
Czytaj oryginał (ang.) |
| Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains? |
Zai Lab Limited (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-02-24 13:25:40 |
Czytaj oryginał (ang.) |
| Here's Why 'Trend' Investors Would Love Betting on Zai Lab Limited (ZLAB) |
Zai Lab Limited (ZLAB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2025-02-24 11:50:37 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade |
The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-01-28 12:56:17 |
Czytaj oryginał (ang.) |
| Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025 |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website. |
businesswire.com |
2025-01-28 09:30:00 |
Czytaj oryginał (ang.) |
| Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC) |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC). “Receiving an Orphan Drug Designation for ZL-1310 recognizes its potential to treat patients with SCLC. These patients have an urgent need for innovative treatment opt. |
businesswire.com |
2025-01-23 01:15:00 |
Czytaj oryginał (ang.) |
| Zai Lab: Rapidly Improving Outlook Bodes Well For The Future |
Zai Lab Limited is transitioning from a "Hold" to a "Buy" rating due to rapid revenue growth and upcoming potential approvals. ZLAB's strategy involves in-licensing U.S.-approved drugs for the Chinese market, with key products like Zejula, Qinlock, Nuzyra, Vyvgart, and Optune driving revenue. Despite high costs, ZLAB's consistent quarterly revenue growth and a strong cash position indicate a promising future. |
seekingalpha.com |
2024-12-26 16:31:42 |
Czytaj oryginał (ang.) |
| Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock? |
Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-24 15:01:11 |
Czytaj oryginał (ang.) |
| Zai Lab Announces Participation in Investor Conference in January 2025 |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conference in January 2025: 43rd Annual J.P. Morgan Healthcare Conference Presentation: Tuesday, January 14, 2025, 1:30 p.m. PST Location: San Francisco A live webcast of the presentation will be available on the Investor Relations page of Zai Lab's website at ir.zailaboratory.com/webcasts-present. |
businesswire.com |
2024-12-12 09:30:00 |
Czytaj oryginał (ang.) |
| Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer |
SHANGHAI & CAMBRIDGE, Mass. & ROOT, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally adv. |
businesswire.com |
2024-12-02 09:02:00 |
Czytaj oryginał (ang.) |
| Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2024 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: AUGTYRO® (repotrectinib) is included in the NRDL for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC); NUZYRA® (omadacycline) is ren. |
businesswire.com |
2024-11-28 01:05:00 |
Czytaj oryginał (ang.) |
| Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam) |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in mainland China. Through this collaboration, Zai Lab will leverage the industry-leading commercialization inf. |
businesswire.com |
2024-11-21 06:00:00 |
Czytaj oryginał (ang.) |
| Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the anticipated closing of its previously announced underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS. In addition, Zai Lab today announced that the underwriters in the offering fully exercis. |
businesswire.com |
2024-11-18 11:15:00 |
Czytaj oryginał (ang.) |
| Zai Lab Announces Pricing of Public Offering of American Depositary Shares |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS. The gross proceeds to Zai Lab from the offering, before deducting underwriting discounts and commissions and other offeri. |
businesswire.com |
2024-11-14 21:43:00 |
Czytaj oryginał (ang.) |
| Zai Lab Announces Proposed Public Offering of American Depositary Shares |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $200.0 million of American depositary shares (“ADSs”), each representing ten ordinary shares of the Company with a par value of $0.000006 per share. All ADSs will be offered by Zai Lab. Zai Lab expects to grant the underwriters a 30-day option to p. |
businesswire.com |
2024-11-13 18:12:00 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics |
The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-12 15:00:27 |
Czytaj oryginał (ang.) |
| Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript |
Zai Lab Limited (NASDAQ:ZLAB ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado – President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citigroup Operator Hello, ladies and gentlemen. Thank you for standing by. |
seekingalpha.com |
2024-11-12 13:53:10 |
Czytaj oryginał (ang.) |
| Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate updates. “In the third quarter, we delivered strong commercial results, maintained financial discipline, and continued to advance our global pipeline of innovative medicines,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. “The launch of VYVGART® has been a. |
businesswire.com |
2024-11-12 08:30:00 |
Czytaj oryginał (ang.) |
| Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China's National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CI. |
businesswire.com |
2024-11-11 09:30:00 |
Czytaj oryginał (ang.) |
| Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company's Phase 3 multi-center trial evaluating the safety and efficacy of KarXT (xanomeline and trospium chloride) in China. Consistent with previous global studies, the registrational bridging trial met its primary endpoint, with KarXT demonstrating a statistically significant 9.2-point reduction in the Positive and Negative Syndrome Scale (PANSS) total sc. |
businesswire.com |
2024-10-29 09:30:00 |
Czytaj oryginał (ang.) |
| Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last? |
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-10-25 10:41:15 |
Czytaj oryginał (ang.) |
| ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC), at the EORTC-NCI-AACR (ENA) Symposium 2024 in Barcelona, Spain, as an oral presentation during the plenary session. ZL-1310 is being tested in patients with previously treated extensive-stage Small Cell Lung Cancer (ES-SCLC) after at least one prior platinum-bas. |
businesswire.com |
2024-10-24 09:15:00 |
Czytaj oryginał (ang.) |
| Zai Lab Announces Participation in November and December Investor Conferences |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in November and December 2024: Goldman Sachs APAC Healthcare Corporate Day 2024 Time: November 5-8, 2024 Location: Hong Kong, Hong Kong Jefferies London Healthcare Conference Fireside Chat: Tuesday, November 19, 2024,1:30 p.m. GT Location: Aldwych, London Citi's 2024 Global Healthcare. |
businesswire.com |
2024-10-18 11:30:00 |
Czytaj oryginał (ang.) |
| Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, the Company's investigational DLL3-targeted antibody-drug conjugate (ADC), in patients with advanced stage small cell lung cancer (SCLC). The live conference call and webcast will take place on Thursday, October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT). Conference Call and Webcast Information Lis. |
businesswire.com |
2024-10-17 12:00:00 |
Czytaj oryginał (ang.) |
| Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024 |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the third quarter of 2024 and recent corporate updates, before the opening of the U.S. equity markets on Tuesday, November 12, 2024. The Company will host a live conference call and webcast on the same date, at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website. |
businesswire.com |
2024-10-16 11:30:00 |
Czytaj oryginał (ang.) |
| Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024 |
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today announced that data from a Phase 1 study of ZL-1310, the Company's investigational antibody-drug conjugate (ADC), will be presented during a plenary session at the EORTC-NCI-AACR Symposium (ENA) 2024 taking place October 23-25, in Barcelona, Spain. The preliminary results from the ongoing, open-label, multicenter clinical trial (NCT06179069) will address the potential of ZL-1310 as a novel. |
businesswire.com |
2024-10-09 11:00:00 |
Czytaj oryginał (ang.) |